http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-081975-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70ebe392b4988c5479996055ae123c27 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
| filingDate | 2011-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeb59e654aa69739e9a479864b8ccad5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69e13b7d45f14cb64f427f5ed09b3d19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ac4a30763f5bc031a38eaebb8617447 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c71942d2bafc8e4ee07e9da75e93c56a |
| publicationDate | 2012-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-081975-A1 |
| titleOfInvention | GLUCAGON ANALOGS |
| abstract | This provides materials and procedures to promote weight loss or prevent weight gain without affecting glycemic control. In particular, glucagon analog peptides effective in such procedures are provided. The peptides can mediate their effect by having increased selectivity for the GLP-1 receptor compared to human glucagon. Claim 1: A compound having the formula: R1-XZ-R2 wherein R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2; X is a peptide having the formula: His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-X16-X17-Arg-Ala-X20-Asp -Phe-Ile-Glu-Trp-Leu-X27-X28-X29 in which X2 is selected from Ser and Aib; X16 is selected from Glu and Y; X17 is selected from Arg and Y; X20 is selected from Lys and Y; X27 is selected from Leu and Y; X28 is selected from Ser and Y or is absent; X29 is Ala or is absent; in which at least one of X16, X17, X20, X27 and X28 is Y; in which each remainder Y is independently selected from Lys, Cys and Orn; wherein the side chain of at least one amino acid residue Y of X is conjugated to a lipophilic substituent having the formula: (i) Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of Y; or (ii) Z1Z2, in which Z1 is a lipophilic moiety, Z2 is a spacer and Z1 is conjugated to the side chain of Y by means of Z2; and Z is absent or is a sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2010-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.